| First Author | Caria CA | Year | 2024 |
| Journal | Cells | Volume | 13 |
| Issue | 14 | PubMed ID | 39056767 |
| Mgi Jnum | J:352612 | Mgi Id | MGI:7706469 |
| Doi | 10.3390/cells13141185 | Citation | Caria CA, et al. (2024) Post-GWAS Validation of Target Genes Associated with HbF and HbA(2) Levels. Cells 13(14) |
| abstractText | Genome-Wide Association Studies (GWASs) have identified a huge number of variants associated with different traits. However, their validation through in vitro and in vivo studies often lags well behind their identification. For variants associated with traits or diseases of biomedical interest, this gap delays the development of possible therapies. This issue also impacts beta-hemoglobinopathies, such as beta-thalassemia and sickle cell disease (SCD). The definitive cures for these diseases are currently bone marrow transplantation and gene therapy. However, limitations regarding their effective use restrict their worldwide application. Great efforts have been made to identify whether modulators of fetal hemoglobin (HbF) and, to a lesser extent, hemoglobin A2 (HbA(2)) are possible therapeutic targets. Herein, we performed the post-GWAS in vivo validation of two genes, cyclin D3 (CCND3) and nuclear factor I X (NFIX), previously associated with HbF and HbA(2) levels. The absence of Ccnd3 expression in vivo significantly increased g (HbF) and d (HbA(2)) globin gene expression. Our data suggest that CCND3 is a possible therapeutic target in sickle cell disease. We also confirmed the association of Nfix with gamma-globin gene expression and present data suggesting a possible role for Nfix in regulating Kruppel-like transcription factor 1 (Klf1), a master regulator of hemoglobin switching. This study contributes to filling the gap between GWAS variant identification and target validation for beta-hemoglobinopathies. |
